Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Current Deferred Revenue (2020 - 2025)

Elicio Therapeutics filings provide 4 years of Current Deferred Revenue readings, the most recent being $694000.0 for Q4 2023.

  • On a quarterly basis, Current Deferred Revenue fell 51.67% to $694000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $694000.0, a 51.67% decrease, with the full-year FY2023 number at $694000.0, down 51.67% from a year prior.
  • Current Deferred Revenue hit $694000.0 in Q4 2023 for Elicio Therapeutics, down from $1.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $5.2 million in Q2 2021 to a low of $653000.0 in Q1 2022.
  • Median Current Deferred Revenue over the past 4 years was $2.3 million (2021), compared with a mean of $2.6 million.
  • The widest YoY moves for Current Deferred Revenue: up 37.59% in 2022, down 82.78% in 2022.
  • Elicio Therapeutics' Current Deferred Revenue stood at $3.9 million in 2020, then tumbled by 41.63% to $2.3 million in 2021, then tumbled by 37.59% to $1.4 million in 2022, then crashed by 51.67% to $694000.0 in 2023.
  • The last three reported values for Current Deferred Revenue were $694000.0 (Q4 2023), $1.7 million (Q3 2023), and $1.4 million (Q4 2022) per Business Quant data.